Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Common Equity: 2023-2024

Historic Common Equity for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $133.6 million.

  • Inhibrx Biosciences' Common Equity fell 79.36% to $36.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year decrease of 79.36%. This contributed to the annual value of $133.6 million for FY2024, which is 207.07% up from last year.
  • As of FY2024, Inhibrx Biosciences' Common Equity stood at $133.6 million, which was up 207.07% from $43.5 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Common Equity ranged from a high of $133.6 million in FY2024 and a low of $43.5 million during FY2023.
  • For the 2-year period, Inhibrx Biosciences' Common Equity averaged around $88.5 million, with its median value being $88.5 million (2023).
  • Data for Inhibrx Biosciences' Common Equity shows a peak YoY soared of 207.07% (in 2024) over the last 5 years.
  • Over the past 2 years, Inhibrx Biosciences' Common Equity (Yearly) stood at $43.5 million in 2023, then soared by 207.07% to $133.6 million in 2024.